Feedback from real users of Lazertinib on its efficacy and side effects

Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), mainly used to treat breast cancer Patients with non-small cell lung cancer (NSCLC) with pan>EGFR sensitive mutations, especially those with T790M mutations, have a significant effect. With the widespread clinical application of lanzatinib, more and more real users have shared their experiences of its efficacy and side effects. This feedback provides valuable reference and confidence for new patients.

Lanzatinib has excellent performance in controlling tumor progression. Most patients report that their symptoms are significantly relieved after taking the medicine, such as cough reduction, breathing smoothness, and physical recovery. Clinical data shows that lanzertinib has a higher objective response rate in patients with EGFR mutations. Imaging examinations of many patients show that their tumors have significantly shrunk or stabilized within a few months of treatment. Some patients reported that the extended survival brought about by lanzetinib significantly improved their quality of life, allowing them to respond more actively to the disease and treatment process.

Regarding side effects, compared with the earlier generation EGFR inhibitors, the tolerability of lanzatinib has been improved, but there are still certain adverse reactions. Among real users, the most common side effects include skin problems (such as rash, dryness, itching), mild diarrhea, and fatigue. These side effects are usually mild and manageable, and most patients are relieved by topical medication, dietary modification, or temporary dose reduction. A small number of patients have reported abnormal liver function or signs of interstitial lung disease, which require close monitoring and timely communication with doctors. Overall, the side effects of lanzetinib are acceptable in most patients, and adverse reactions lead to less discontinuation of treatment.

In addition, some patients specifically mentioned the efficacy of lanzertinib in patients with brain metastases, believing that it has a strong ability to penetrate the blood-brain barrier and can effectively control brain lesions and reduce neurological symptoms. This is particularly important for patients with advanced lung cancer, as brain metastasis is a common and serious complication. Patients reported that after using lanzetinib, symptoms such as headaches and blurred vision were relieved, and their daily living abilities were improved, which greatly improved the treatment experience.

In general, lanzetinib has shown good efficacy and a mild side effect spectrum in real clinical applications. Patients generally believe that it has a significant effect in prolonging survival and improving quality of life, and although side effects exist, they are mostly manageable. At the same time, both doctors and patients emphasize the importance of standardized medication use and regular monitoring to detect and respond to potential adverse reactions in a timely manner. In the future, with the use of more patients and the accumulation of longer follow-up data, lanzitinib is expected to become an important treatment option for patients with EGFR mutated non-small cell lung cancer.

Reference materials:https://www.drugs.com/